Search results
Showing 1561 to 1575 of 1688 results for carers
Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.
Nivolumab for previously treated advanced renal cell carcinoma (TA417)
Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
In development [GID-TA11139] Expected publication date: TBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358
In development [GID-TA11601] Expected publication date: TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued [GID-TA11020]
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued [GID-TA11244]
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development [GID-TA11022] Expected publication date: TBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]
In development [GID-TA11044] Expected publication date: TBC
In development [GID-TA11166] Expected publication date: TBC